

ASX Release

SUDA ESTABLISHES SCIENTIFIC ADVISORY BOARD FOR SUD-018 ANAGRELIDE ORAL SPRAY

PERTH, AUSTRALIA – 15 May 2018: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, today announced the appointment of two leading specialists in the role of platelets in cancer to its Scientific Advisory Board (SAB) for SUD-018, the Company's first-in-class oral spray of the platelet-lowering drug, anagrelide, for the treatment of solid cancers. These experts are providing advice and guidance to SUDA on the development of SUD-018. The two appointments to the SAB are Dr Nailin Li and Dr Richard Franklin.

Dr Nailin Li is an associate professor at the Karolinska Institute in Sweden. He received his medical education in China and doctoral education at Karolinska Institute in Sweden. Dr Li's main research interests are thrombotic and inflammatory mechanisms in atherosclerosis, platelet angiogenic activities in arterial remodelling and cancer progression, and clinical evaluation of anti-platelet drugs. He is an internationally recognised researcher in platelet functional studies and platelet-T effector cell interactions.

Dr Richard Franklin gained his PhD from Surrey University in the UK in Drug Metabolism and Pharmacokinetics and subsequently worked in research and development in the pharmaceutical industry. Dr Franklin has worked for several major drug companies including Glaxo, Wyeth, Sterling Winthrop, & AstraZeneca. Latterly he was head of New Product Innovation at Shire Pharmaceuticals where he is credited with filing over forty patents on potential new drug products.

SUDA's CEO, Mr Stephen Carter, commented: "We are pleased to have attracted two of the world's leading experts with unparalleled clinical and medical experience in the role of platelets in cancer progression and the development of anti-cancer drugs. These key opinion leaders are advising SUDA on the development of SUD-018. Their involvement provides further endorsement of the merits of our acquisition of the global intellectual property relating to anagrelide, an anti-thrombotic agent that has shown promise as a novel anti-cancer agent."



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 5555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com

About anagrelide

Anagrelide is currently used as an anti-thrombotic agent to reduce elevated levels of platelets. Scientists have identified that platelets also provide essential growth factors that nourish cancer cells and enable them to take hold and develop into tumours. Hence, those patients with the highest platelet numbers are least likely to survive. Anagrelide has the potential to be developed as an effective anti-cancer agent, but is fundamentally limited in its current formulation by cardio-stimulatory side-effects. An oro-mucosal spray formulation of anagrelide could minimise these side-effects by avoiding first-pass generation of a highly potent cardio-excitatory metabolite of the drug in the liver.